Terence Hall

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

Vincenzo Mazzaferro, Bassel F. El‐Rayes, Michele Droz Dit Busset et al. · British Journal of Cancer · 2018 · 375 citations · Full text

Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092

Yi Yu, Ronald E. Savage, Sudharshan Eathiraj et al. · PLoS ONE · 2015 · 120 citations · Full text

Chemoprevention Strategy, Immunology, Cancer Biology +18

Discovery and Optimization of a Series of 3-(3-Phenyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors

Mark A. Ashwell, Jean‐Marc Lapierre, Christopher J. Brassard et al. · Journal of Medicinal Chemistry · 2012 · 98 citations · Full text

Chemical Biology, Pharmaceutical Chemistry, Biophysical Screening Strategy +19

Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation

Terence Hall, Yi Yu, Sudharshan Eathiraj et al. · PLoS ONE · 2016 · 84 citations · Full text

Fgfr Pathway, Immunology, Cancer Biology +21

ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations.

Vincenzo Mazzaferro, Bassel F. El‐Rayes, Christian Cotsoglou et al. · Journal of Clinical Oncology · 2017 · 30 citations

Fgfr Genetic Aberrations, Pathology, Tumor Biology +17